NVSNovartis PharmaceuticalsSigning up patients
An Open-label Study Comparing Lutetium (177Lu) Vipivotide Tetraxetan Versus Observation in PSMA Positive OMPC.
Oligometastatic Prostate Cancer (OMPC)
0Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 3
- Patients
- 450 (planned)
- Started
- Mar 12, 2024
- Main results expected
- Apr 25, 2028
- Fully finished
- Oct 3, 2031
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Blinded Independent Review Committee (BIRC) assessed Metastasis Free Survival (MFS)
Measured over: From date of randomization until first evidence of radiographically detectable bone or soft tissue distant metastasis or death due to any cause, whichever occurs first, assessed up to approximately 30 months
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT05939414 · record last updated 2026-10-21 · checked 2026-11-09 15:47 UTC